

Ian Ford

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/443719/publications.pdf>

Version: 2024-02-01

40
papers

4,282
citations

331259

21
h-index

315357

38
g-index

40
all docs

40
docs citations

40
times ranked

6889
citing authors

#	ARTICLE	IF	CITATIONS
1	The interleukin-6 receptor as a target for prevention of coronary heart disease: a mendelian randomisation analysis. <i>Lancet, The</i> , 2012, 379, 1214-1224.	6.3	886
2	Women and men with stable coronary artery disease have similar clinical outcomes: insights from the international prospective CLARIFY registry. <i>European Heart Journal</i> , 2012, 33, 2831-2840.	1.0	560
3	SCORE2 risk prediction algorithms: new models to estimate 10-year risk of cardiovascular disease in Europe. <i>European Heart Journal</i> , 2021, 42, 2439-2454.	1.0	491
4	Ivabradine in Stable Coronary Artery Disease without Clinical Heart Failure. <i>New England Journal of Medicine</i> , 2014, 371, 1091-1099.	13.9	399
5	Cardiovascular event rates and mortality according to achieved systolic and diastolic blood pressure in patients with stable coronary artery disease: an international cohort study. <i>Lancet, The</i> , 2016, 388, 2142-2152.	6.3	357
6	Intravenous Iron in Patients Undergoing Maintenance Hemodialysis. <i>New England Journal of Medicine</i> , 2019, 380, 447-458.	13.9	321
7	The design of a prospective study of pravastatin in the elderly at risk (PROSPER). <i>American Journal of Cardiology</i> , 1999, 84, 1192-1197.	0.7	310
8	Prevalence of Anginal Symptoms and Myocardial Ischemia and Their Effect on Clinical Outcomes in Outpatients With Stable Coronary Artery Disease. <i>JAMA Internal Medicine</i> , 2014, 174, 1651.	2.6	118
9	C-Reactive Protein and Prediction of Coronary Heart Disease and Global Vascular Events in the Prospective Study of Pravastatin in the Elderly at Risk (PROSPER). <i>Circulation</i> , 2007, 115, 981-989.	1.6	112
10	Fractional flow reserve derived from computed tomography coronary angiography in the assessment and management of stable chest pain: the FORECAST randomized trial. <i>European Heart Journal</i> , 2021, 42, 3844-3852.	1.0	74
11	Heart Rate and Use of Beta-Blockers in Stable Outpatients with Coronary Artery Disease. <i>PLoS ONE</i> , 2012, 7, e36284.	1.1	70
12	Genetically determined NLRP3 inflammasome activation associates with systemic inflammation and cardiovascular mortality. <i>European Heart Journal</i> , 2021, 42, 1742-1756.	1.0	63
13	Methods of a large prospective, randomised, open-label, blinded end-point study comparing morning versus evening dosing in hypertensive patients: the Treatment In Morning versus Evening (TIME) study. <i>BMJ Open</i> , 2016, 6, e010313.	0.8	58
14	Long-term outcomes of chronic coronary syndrome worldwide: insights from the international CLARIFY registry. <i>European Heart Journal</i> , 2020, 41, 347-356.	1.0	55
15	Intravenous Iron Dosing and Infection Risk in Patients on Hemodialysis: A Prespecified Secondary Analysis of the PIVOTAL Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1118-1127.	3.0	55
16	Vitamin K Supplementation to Improve Vascular Stiffness in CKD: The K4Kidneys Randomized Controlled Trial. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 2434-2445.	3.0	49
17	Rationale, design, and baseline characteristics of the <scp>CLARIFY</scp> registry of outpatients with stable coronary artery disease. <i>Clinical Cardiology</i> , 2017, 40, 797-806.	0.7	40
18	Randomized Trial Comparing Proactive, High-Dose versus Reactive, Low-Dose Intravenous Iron Supplementation in Hemodialysis (PIVOTAL): Study Design and Baseline Data. <i>American Journal of Nephrology</i> , 2018, 48, 260-268.	1.4	30

#	ARTICLE	IF	CITATIONS
19	Associations of Cytomegalovirus Infection With All-Cause and Cardiovascular Mortality in Multiple Observational Cohort Studies of Older Adults. <i>Journal of Infectious Diseases</i> , 2021, 223, 238-246.	1.9	30
20	International Observational Analysis of Evolution and Outcomes of Chronic Stable Angina: The Multinational CLARIFY Study. <i>Circulation</i> , 2021, 144, 512-523.	1.6	25
21	Randomized Trial of Prescription of Intradialytic Exercise to Improve Quality of Life in Patients Receiving Hemodialysis. <i>Kidney International Reports</i> , 2021, 6, 2159-2170.	0.4	22
22	Relationship between physical activity and long-term outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2020, 27, 426-436.	0.8	21
23	Impact of smoking on cardiovascular outcomes in patients with stable coronary artery disease. <i>European Journal of Preventive Cardiology</i> , 2021, 28, 1460-1466.	0.8	21
24	Exercise programme to improve quality of life for patients with end-stage kidney disease receiving haemodialysis: the PEDAL RCT. <i>Health Technology Assessment</i> , 2021, 25, 1-52.	1.3	19
25	Chronotherapy in hypertension: the devil is in the details. <i>European Heart Journal</i> , 2020, 41, 1606-1607.	1.0	18
26	Invasive Versus Medical Management in Patients With Prior Coronary Artery Bypass Surgery With a Non-ST Segment Elevation Acute Coronary Syndrome. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e007830.	1.4	17
27	Prevalence of diabetes and impact on cardiovascular events and mortality in patients with chronic coronary syndromes, across multiple geographical regions and ethnicities. <i>European Journal of Preventive Cardiology</i> , 2022, 28, 1795-1806.	0.8	13
28	Vertebral artery stenting to prevent recurrent stroke in symptomatic vertebral artery stenosis: the VIST RCT. <i>Health Technology Assessment</i> , 2019, 23, 1-30.	1.3	12
29	Incident heart failure in outpatients with chronic coronary syndrome: results from the international prospective CLARIFY registry. <i>European Journal of Heart Failure</i> , 2020, 22, 804-812.	2.9	9
30	Non-invasive versus invasive management in patients with prior coronary artery bypass surgery with a non-ST segment elevation acute coronary syndrome: study design of the pilot randomised controlled trial and registry (CABG-ACS). <i>Open Heart</i> , 2016, 3, e000371.	0.9	7
31	Stroke in hemodialysis patients randomized to different intravenous iron strategies: a prespecified analysis from the PIVOTAL trial. <i>Kidney360</i> , 2021, 2, 10.34067/KID.0004272021.	0.9	7
32	Simple risk models to predict cardiovascular death in patients with stable coronary artery disease. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2021, 7, 287-294.	1.8	3
33	Prevalence, Incidence and Prognostic Implications of Left Bundle Branch Block in Patients with Chronic Coronary Syndromes (From the CLARIFY Registry). <i>American Journal of Cardiology</i> , 2021, 150, 40-46.	0.7	3
34	Use of risk scores to identify lower and higher risk subsets among COMPASS-eligible patients with chronic coronary syndromes. Insights from the CLARIFY registry. <i>Clinical Cardiology</i> , 2021, 44, 58-65.	0.7	2
35	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , 2021, 8, e001453.	0.9	2
36	Authors' Reply. <i>Journal of the American Society of Nephrology: JASN</i> , 2020, 31, 1654-1654.	3.0	1

#	ARTICLE	IF	CITATIONS
37	Invasive versus medically managed acute coronary syndromes with prior bypass (CABG-ACS): insights into the registry versus randomised trial populations. <i>Open Heart</i> , 2021, 8, .	0.9	1
38	An analysis of vascular access thrombosis events from the Proactive IV Iron Therapy in Hemodialysis Patients (PIVOTAL) trial. <i>Kidney International Reports</i> , 2022, , .	0.4	1
39	Cardiovascular risk of chronic coronary syndrome patients according to vascular phenotype, diabetes, and smoking. <i>European Journal of Preventive Cardiology</i> , 2020, , .	0.8	0
40	Low-dose intracoronary alteplase during primary percutaneous coronary intervention in patients with acute myocardial infarction: the T-TIME three-arm RCT. <i>Efficacy and Mechanism Evaluation</i> , 2020, 7, 1-86.	0.9	0